Presence and Quantity of COX-2 in Lymph Node Metastases of Patients with Head and Neck Cancer

COX-2 expression in primary lesions, as well as lymph node metastases, appears to identify HNSCC patients at higher risk in all tumor sites. Adjuvant therapeutic approaches targeting COX-2 might be a promising tool in this patient population.